The fastest way to turn routine replenishment into a repayment problem is to dispense first, reconcile later, and assume the software caught everything. In 2026, that approach is indefensible. Drug Channels reported that discounted purchases under the 340B program reached $100 billion in 2025, up 23% from 2024, with hospitals accounting for 87% of 340B purchases. At that scale, inventory discipline isn't back-office housekeeping. It's the control that shows your accumulations were earned and your purchases were appropriate.
A covered entity doesn't need an elaborate theory of inventory management. It needs records that match how the drug moved, how the claim qualified, and how replenishment was generated. When those three pieces don't align, the problem usually appears in one of two places: duplicate-discount risk tied to claim designation, or diversion risk tied to a bad accumulator feed, incorrect location mapping, or an improper purchasing pattern.
Start with replenishment logic, not shelf counts
Physical inventory matters, but 340B compliance usually fails earlier, in the transaction logic. If the split-billing setup can't reliably separate eligible from ineligible use at the claim level, every downstream inventory report is simply a polished version of bad source data.
For that reason, replenishment criteria should be the primary control in 2026. Before a drug is reordered on a 340B account, the covered entity should be able to show why the dispense qualified under its documented rules and why the accumulator captured the record. A system that depends on manual cleanup after the fact has an unstable inventory file.
Here is the situation every 340B administrator recognizes: a fast-moving item is draining from the shelf, the wholesaler order has to go out, and the split-billing file has not finished adjudicating or been reviewed. The buyer places the order based on expected accumulations. Operationally, that works. From a compliance standpoint, it leaves a gap between actual qualified use and assumed qualified use. Claim reversals, payer corrections, prescriber-mapping problems, or location edits can later hit the file, leaving the replenishment trail unable to cleanly support what was purchased.
The practical fix is unglamorous. Lock down the timing and authority for 340B replenishment decisions, and make sure pharmacy operations, purchasing, and the accumulator owner follow the same cutoff rules. When qualification remains unresolved, handle the transaction conservatively until the record is clean. A short-term operational inconvenience is easier to defend than a purchase trail built on guesswork.
Mixed-use drugs expose weak carve-in and carve-out controls
Risk rises when the same product moves through different billing pathways, locations, or patient settings. That is where covered entities start relying on the software to distinguish every situation simply because claims are flowing. Claims flow is not proof of compliant purchasing.
For drugs dispensed or administered in settings with different eligibility treatment, the central control is location governance, not just a replenishment report. The covered entity needs an auditable way to show that the event came from the correct registered site, that the system applied the correct payer or Medicaid treatment, and that the purchase account matched the qualified event. If one of those links is missing, inventory integrity is weak even when the shelf count balances.
Exceptions are where administrators get tripped up: a clinic move not reflected everywhere, a new cost center feeding the accumulator before governance caught up, or an internal product transfer without a clear record of why it occurred. None of these events looks dramatic at the time. They become serious when someone asks the covered entity to trace a 340B unit from qualification to purchase to dispense.
Drug Channels also noted a webinar focused on 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders. That framing applies to inventory work. Market and policy disputes draw attention, but inventory controls are where those pressures land. Responding to uncertainty with ad hoc purchasing or loose exception handling creates a larger audit problem than the original operational issue.
Specialty and high-cost products need tighter exception review
Not every product requires the same manual attention. Expensive and operationally sensitive products do. Drug Channels identified more than 1,900 dispensing locations with specialty pharmacy accreditation in 2025 and said the overall number of accredited locations grew by only 3% in 2025. It also reported that the three largest specialty pharmacies accounted for two-thirds of total prescription revenues from pharmacy-dispensed specialty drugs. Those figures do not prescribe an inventory model, but they underscore how concentrated and demanding specialty dispensing remains.
For 340B covered entities, the implication is straightforward. Products with specialty workflows, limited-distribution constraints, tighter handling requirements, or more complicated claim pathways should not move through the same exception queue as routine replenishment. When the accumulator sends every product through one generic reconciliation process, volume can hide high-risk items.
A second review belongs on any transaction that does not behave as policy expects: a mismatch between the dispense record and purchasing account, an out-of-sequence accumulation, a reversal arriving after replenishment activity, or a location issue that changes eligibility status. The goal is not manual review of everything. It is finding the transactions where a bad 340B purchase would be hardest to unwind and easiest to miss.
Entities dispensing through specialty channels also need to be candid about data latency. Inventory reports can look clean while the underlying claim files are still settling. Treating early system output as final builds false confidence into the audit trail.
Privacy, data matching, and audit trails now belong in inventory policy
By 2026, inventory management is also a data-governance function. CMS published a 2026 Federal Register notice on the re-establishment of a matching program between CMS and the Office of Personnel Management under the Privacy Act. The notice is not a 340B inventory rule, but it reflects the broader reality that government oversight depends on matching records across systems.
The same lesson applies internally. An inventory policy that does not explain how patient, prescriber, location, and claim data enter the split-billing or replenishment system is incomplete. A clean perpetual inventory count will not fix feeder data that were mapped incorrectly or changed without governance.
The strongest inventory policies therefore read less like warehouse procedures and more like control documents. They identify who can add a location, who can change drug mapping, how reversals are handled, when accumulations are final enough for replenishment, and how overrides are documented. They also make clear that purchasing staff cannot solve a data problem by ordering around it.
One sentence belongs in every serious 340B inventory policy: if a transaction can't be supported, it can't be replenished on a 340B account.
At this scale, sloppiness is visible as well as expensive. Drug Channels' 2025 program estimate of $100 billion should end the idea that inventory control is a secondary task inside 340B. The record path from qualified use to replenishment is the part that has to hold up. In 2026, that is where the bet sits.
